Company Profile
Gain Therapeutics Stock Price, News & Catalysts
- Ticker:
- GANX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
1.78 USD (+3.49%)
Close
Last updated: September 17, 2026
78.1M USD
Market cap
Why the stock is moving
Following the latest company update, āGain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conferenceā, GANX closed up 3.49% at $1.78 on Sep 17, 2026. The move occurred in the trading session associated with this conference / presentation update.
Company overview
Allosteric Small-Molecule Platform
Gain Therapeutics uses its Magellan discovery platform to identify allosteric small molecules that restore the function of disease-associated proteins. Its lead efforts focus on neurodegenerative disorders.
GT-02287
GT-02287 is an oral, brain-penetrant modulator of glucocerebrosidase being developed for Parkinson's disease with or without a GBA1 mutation. The candidate is intended to correct lysosomal dysfunction and potentially modify disease biology.
Earlier Discovery Programs
The company's preclinical pipeline includes GT-04686 and related GCase modulators identified through the same structure-guided platform, providing follow-on opportunities in neurodegeneration.
Future catalysts
- Completion of the nine-month Phase 1b extension study of GT-02287 in October 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Gain Therapeutics (GANX)?
Gain Therapeutics (GANX) most recently closed at 1.78 USD, a +3.49% move versus the previous session.
What is the market cap of Gain Therapeutics (GANX)?
Gain Therapeutics currently has a market capitalization of 78.1M USD on BioPharmSignal.
What does Gain Therapeutics do?
Allosteric Small-Molecule Platform Gain Therapeutics uses its Magellan discovery platform to identify allosteric small molecules that restore the function of disease-associated proteins. Its lead efforts focus on neurodegenerative disorders. GT-02287 GT-02287 is an oral, brain-penetrant modulator of glucocerebrosidase being developed for Parkinson's disease...
On which exchange is GANX stock listed?
Gain Therapeutics (GANX) is associated with NASDAQ, Switzerland, Biopharma.
What is GT-02287?
Completion of the nine-month Phase 1b extension study of GT-02287 in October 2026.
Which conditions is Gain Therapeutics targeting with GT-02287?
Completion of the nine-month Phase 1b extension study of GT-02287 in October 2026.
How does Gain Therapeutics describe recent progress with GT-02287?
Completion of the nine-month Phase 1b extension study of GT-02287 in October 2026.
What is GT-04686?
Earlier Discovery Programs The company's preclinical pipeline includes GT-04686 and related GCase modulators identified through the same structure-guided platform, providing follow-on opportunities in neurodegeneration.